Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the kinetics of IgA secreting cells (IgASCs) and secretory IgA (sIgA) level in small intestine induced by intranasal immunization with Toxoplasma gondii soluble tachyzoite antigen (STAg) in mice.
Methods: Ninety-six 5 to 6-week old BALB/c mice were randomly divided into immunity and control groups. Mice of the immunity group were each intranasally immunized with STAg 20 microg in 20 microl PBS, twice at an interval of 2 weeks, while the control mice were each given 20 microl PBS. All mice were challenged intragastrically with 1 x 10(4) tachyzoites in 0.5 ml per mouse in 1 week after the last immunization. The body weight and infection incidence of mice were recorded. Eight mice of each group were sacrificed on the day 6, 7, 8, 9, 10 and 11 post infection, respectively. The quantity of IgASCs in mucosa of duodenum, jejunum and ileum was detected by immunohistochemistry. The sIgA in intestinal washes were determined by ELISA.
Results: All mice fell ill post infection, but the symptom of mice in the immunity group was milder, the increasing level of body weight of mice in the immunity group was higher considerably than that in the control group (P < 0.05). Two mice died in control group on the 7th day after infection. sIgA level in intestinal washes increased continually in two groups, but the increasing level in the immunity group was higher than that of the control (P < 0.05). The number of IgASCs in duodenum increased slightly in the control group, but increased continuously and maintained a high level after 9 d in the immunity group, for instance, 20.65 +/- 1.67 in the immunity group and 12.30 +/- 2.67 in the control. The correlation of the sIgA level in intestinal washes and the quantitative change of IgASCs in duodenum was positive in the immunity group (r = 0.566, P < 0.05) and the control (r = 0.378, P < 0.05). The number of IgASCs in jejunum decreased in the control group but increased then slightly decreased after 9 d in the immunity group. Positive correlation between the sIgA level in intestinal washes and the quantitative change of IgASCs in jejunum was found in the immunity group (r = 0.218, P > 0.05) but negative in the control (r = -0.557, P < 0.05). The number of IgASCs in ileum declined in the control group but maintained a high level in the immunity group. The correlation between the sIgA level in intestinal washes and the quantitative change of IgASCs in ileum was r = -0.053 (P > 0.05) in the immunity group and r = -0.685 (P < 0.05) in the control.
Conclusion: Intranasal immunization with STAg in mice orally infected with Toxoplasma gondii can increase the number of IgASCs in jejunum and ileum, and enhance the immune barrier function of mucosa in small intestine of mice.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Transcriptomic analysis of immune and metabolic responses in largemouth bass (Micropterus salmoides) challenged with Citrobacter freundii.
J Fish Biol
September 2025
College of Animal Science and Technology, Yangzhou University, Yangzhou, China.
Citrobacter freundii, a common zoonotic pathogen affecting humans, livestock and fish, is recognized for its substantial impact on largemouth bass (Micropterus salmoides) mortality. However, the mechanisms of C. freundii infection in largemouth bass remain poorly understood.
View Article and Find Full Text PDFTCR/BCR Secondary Rearrangement in Autoimmune Diseases: Molecular Mechanisms, Pathogenic Roles, and Therapeutic Frontiers.
Immunol Invest
September 2025
Scientific Research Department, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Autoimmune diseases (AIDs) constitute a group of disorders where the immune system mistakenly attacks the body's tissues. The pathogenesis of AIDs involve a breakdown in immune tolerance, culminating in an immune response that targets autoantigens. In adaptive immunity, secondary rearrangement of T cell receptors (TCRs) and B cell receptors (BCRs) involves sequential V(D)J recombination events during lymphocyte development.
View Article and Find Full Text PDFMolecular Mechanism of Butyrate Modulating Treg/Th17 Balance in UC Through cAMP-PKA/mTOR Axis.
Immunol Invest
September 2025
Department of Function, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, China.
Objective: This study aims to elucidate how butyrate, a short-chain fatty acid, regulates the Treg/Th17 balance in ulcerative colitis (UC) via the cAMP-PKA/mTOR signaling pathway, offering novel treatment strategies.
Methods: Dextran sulfate sodium (DSS) was used to induce ulcerative colitis in a mouse model. Various butyrate dosages were administered to the mice.
Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.
Ann Surg Oncol
September 2025
Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.
Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.